NIPT - Noninvasive Prenatal Test

NIPT (Noninvasive Prenatal Test) is a non-invasive examination for assessing the risk of chromosomal abnormalities in the fetus, allowing for early detection of chromosomal defects, particularly Down syndrome and sex chromosome-related disorders.
The test is non-invasive. It involves taking a blood sample from the mother, which is sent to the laboratory for the extraction of fetal DNA from the mother's blood for analysis.
It is important to understand that this is a screening test, and if an abnormal result is obtained, confirmation is required through chorionic villus sampling (CVS) or amniocentesis.
The test can be performed starting from the 10th week of pregnancy.

Indications for NIPT according to the recommendations of the Israeli Union of Human Genetics:

• Women aged 35 and over (Leumit Gold members are entitled to the test at any age).
• Suspicious ultrasound findings indicate the possibility of a chromosomal abnormality.
• Personal or family history of chromosomal abnormalities detected by NIPT.
• First or second-trimester screening tests indicate an increased risk of chromosomal disorders to be tested by NIPT.
• One of the parents carries a Robertsonian translocation involving chromosomes 18, 13, or 21.

NIPT is less effective in cases of:

• Multifetal pregnancies.
• A pregnancy started as a twin pregnancy with the loss of one of the twins.
• Cases of mosaicism (when only some cells in the body or placenta have chromosomal abnormalities).

Click here for more information about NIPT.